LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient...
NEW BRITAIN, Pa. — THROMBOLEX, Inc., a leader in the development of innovative treatments for pulmonary embolism (PE), announced the interim analysis of the first 150 patients in RAPID-PE, a prospective, multicenter, single-arm study of...
NEW BRITAIN, Pa. — THROMBOLEX, Inc., a leader in the development of innovative treatments for pulmonary embolism (PE), announced the interim analysis of the first 150 patients in RAPID-PE, a prospective, multicenter, single-arm study of...
The company’s technologies include the ALTO® Abdominal Stent Graft System, the AFX®2 Endovascular AAA System, the DETOUR® System for percutaneous bypass in PAD, and the Pounce™ Thrombectomy System.
The company’s technologies include the ALTO® Abdominal Stent Graft System, the AFX®2 Endovascular AAA System, the DETOUR® System for percutaneous bypass in PAD, and the Pounce™ Thrombectomy System.
The new codes, 37X47 and 37X48, describe percutaneous transcatheter renal sympathetic denervation procedures and are expected to become effective January 1, 2028.
The new codes, 37X47 and 37X48, describe percutaneous transcatheter renal sympathetic denervation procedures and are expected to become effective January 1, 2028.
MENLO PARK, Calif.--(BUSINESS WIRE)--Inquis Medical, a medical device company pioneering advanced treatments for venous thromboembolic disease, today announced the U.S. commercial launch of the latest AVENTUS™ Catheter, designed to provide...
MENLO PARK, Calif.--(BUSINESS WIRE)--Inquis Medical, a medical device company pioneering advanced treatments for venous thromboembolic disease, today announced the U.S. commercial launch of the latest AVENTUS™ Catheter, designed to provide...
Open-Motion uses near-infrared light to measure changes in blood flow and blood volume beneath tissue surfaces in real time without invasive procedures.
Open-Motion uses near-infrared light to measure changes in blood flow and blood volume beneath tissue surfaces in real time without invasive procedures.
WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the...
WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the...
Mölnlycke Health Care US, LLC. has launched a new surgical glove range designed to reduce clinician hand exposure to scattered radiation during fluoroscopy-guided, interventional and other image-dependent procedures.
Mölnlycke Health Care US, LLC. has launched a new surgical glove range designed to reduce clinician hand exposure to scattered radiation during fluoroscopy-guided, interventional and other image-dependent procedures.
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...